Your browser doesn't support javascript.
Safety and heart rate changes in Covid-19 patients treated with Remdesivir.
Brunetti, Natale Daniele; Poliseno, Mariacristina; Bottalico, Irene Francesca; Centola, Antonio; Montemurro, Laura; Sica, Salvatore; Santantonio, Teresa; Lo Caputo, Sergio.
  • Brunetti ND; Department of Medical & Surgical Sciences, University of Foggia, Italy. Electronic address: natale.brunetti@unifg.it.
  • Poliseno M; Department of Clinical and Experimental Medicine, University of Foggia, Italy. Electronic address: polisenomc@gmail.com.
  • Bottalico IF; Department of Clinical and Experimental Medicine, University of Foggia, Italy. Electronic address: ibott4@gmail.com.
  • Centola A; Cardiology Department, Policlinico Riuniti University Hospital, Foggia, Italy. Electronic address: centola.antonio79@gmail.com.
  • Montemurro L; Department of Clinical and Experimental Medicine, University of Foggia, Italy. Electronic address: laura.monty91@gmail.com.
  • Sica S; Infectious Diseases Unit Policlinico Riuniti University Hospital, Foggia, Italy. Electronic address: salvatoresica@libero.it.
  • Santantonio T; Department of Clinical and Experimental Medicine, University of Foggia, Italy. Electronic address: teresa.santantonio@unifg.it.
  • Lo Caputo S; Department of Clinical and Experimental Medicine, University of Foggia, Italy. Electronic address: sergio.locaputo@unifg.it.
Int J Infect Dis ; 112: 254-257, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1415455
ABSTRACT

OBJECTIVES:

Limited data are available regarding the occurrence and the extent of cardiac rhythm disturbances in patients with COVID-19 treated with Remdesivir.

METHODS:

We present a case series of 52 patients who underwent daily electrocardiogram (ECG) examination after Remdesivir administration.

RESULTS:

Compared to baseline, a significant heart rate reduction was observed after initiation of Remdesivir; however, no case of severe bradycardia or arrhythmias leading to significant clinical complications or Remdesivir discontinuation occurred. Heart rate reduction was proportional to baseline heart rate values (r=0.75, p<0.001). By multivariate analysis, a less severe clinical presentation of Covid-19 (beta=0.47, p<0.01) was related to lower heart rate levels observed after Remdesivir administration.

CONCLUSIONS:

Despite a significant reduction in heart rate observed after Remdesivir administration, no severe cardiovascular toxicity was observed in Covid-19 patients, even in the case of cardiovascular comorbidities.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Language: English Journal: Int J Infect Dis Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Language: English Journal: Int J Infect Dis Year: 2021
...